CreativeOne Wealth LLC Grows Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

CreativeOne Wealth LLC raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 182.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,446 shares of the company’s stock after acquiring an additional 2,873 shares during the period. CreativeOne Wealth LLC’s holdings in Medpace were worth $1,484,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Renaissance Technologies LLC boosted its position in shares of Medpace by 38.3% in the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock worth $182,692,000 after acquiring an additional 122,800 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Medpace by 55.1% in the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after purchasing an additional 143,481 shares during the last quarter. Westwind Capital boosted its holdings in shares of Medpace by 800.1% in the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock valued at $156,886,000 after purchasing an additional 338,610 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Medpace by 62.3% during the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after buying an additional 119,257 shares during the period. Finally, FMR LLC increased its holdings in shares of Medpace by 11.8% during the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after buying an additional 24,362 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research analyst reports. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. Robert W. Baird increased their target price on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research report on Monday. TD Cowen reduced their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, Redburn Atlantic assumed coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $380.56.

Medpace Price Performance

Medpace stock opened at $338.96 on Friday. The firm’s fifty day moving average price is $338.32 and its 200 day moving average price is $371.75. The company has a market capitalization of $10.53 billion, a price-to-earnings ratio of 29.68, a price-to-earnings-growth ratio of 1.88 and a beta of 1.37. Medpace Holdings, Inc. has a 12-month low of $268.80 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. During the same period in the previous year, the company earned $2.22 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.